INmune Bio Inc

NASDAQ INMB

Data sourced from

and

Daily

Download Data

INmune Bio Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

INmune Bio Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

INmune Bio Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is -3.30 on October 02, 2023, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
INmune Bio Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -6,064.05 on August 07, 2023, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
INmune Bio Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -144.75.

NASDAQ: INMB

INmune Bio Inc

CEO	Dr. Raymond Joseph Tesi M.D.
IPO Date	Feb. 4, 2019
Location	United States
Headquarters	980 North Federal Highway, Boca Raton, FL, United States, 33432
Employees	11
Sector	Healthcare
Industry	Biotechnology

Description

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Key trends